Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
Special Offer: Just $199
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
Most-Upgraded Stocks  
NASDAQ:VRTX

Vertex Pharmaceuticals - VRTX Stock Forecast, Price & News

$315.30
+2.32 (+0.74%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$313.51
▼
$320.93
50-Day Range
$276.78
▼
$321.48
52-Week Range
$185.46
▼
$323.61
Volume
1.11 million shs
Average Volume
1.58 million shs
Market Capitalization
$80.93 billion
P/E Ratio
24.87
Dividend Yield
N/A
Price Target
$305.33

Vertex Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.65 Rating Score
Upside/​Downside
3.2% Downside
$305.33 Price Target
Short Interest
Healthy
1.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.12
Upright™ Environmental Score
News Sentiment
0.58mentions of Vertex Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$1.13 M Sold Last Quarter
Proj. Earnings Growth
5.77%
From $13.00 to $13.75 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

441st out of 1,040 stocks

Pharmaceutical Preparations Industry

213th out of 509 stocks

See Top Rated MarketRank™ Stocks Here
VRTX stock logo

About Vertex Pharmaceuticals (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRTX Stock News Headlines

November 10, 2022 | marketbeat.com
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report? (VRTX)
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.
November 26, 2022 | finance.yahoo.com
Are Robust Financials Driving The Recent Rally In Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Stock?
November 24, 2022 | msn.com
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $7,900 Today
November 24, 2022 | americanbankingnews.com
Vertex Pharmaceuticals (NASDAQ:VRTX) Hits New 52-Week High at $318.59
November 23, 2022 | finance.yahoo.com
GSK to Withdraw Blenrep From U.S. Market on FDA Request
November 22, 2022 | finance.yahoo.com
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 36% Below Their Intrinsic Value Estimate
November 21, 2022 | finance.yahoo.com
Why Vertex Pharmaceuticals (VRTX) is a Top Value Stock for the Long-Term
November 21, 2022 | americanbankingnews.com
Analysts Set Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) PT at $305.33
November 21, 2022 | americanbankingnews.com
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $340.00 Price Target at Argus
November 18, 2022 | finance.yahoo.com
Dow Jones Futures: 7 Investing Rules For A Tricky Market Rally; Tesla Skids To Bear Market Lows
November 18, 2022 | finance.yahoo.com
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 37% Undervalued
November 18, 2022 | finance.yahoo.com
3 Top Growth Stocks to Buy Sooner Rather Than Later
November 17, 2022 | markets.businessinsider.com
6 Analysts Have This to Say About Vertex Pharmaceuticals
November 17, 2022 | finance.yahoo.com
VRTX or TECH: Which Is the Better Value Stock Right Now?
November 16, 2022 | seekingalpha.com
Vertex Pharmaceuticals Incorporated (VRTX) Jefferies London Healthcare Conference (Transcript)
November 16, 2022 | finance.yahoo.com
2 Hot Growth Stocks That Can Continue to Soar in 2023
November 16, 2022 | finance.yahoo.com
Here’s Why Vertex Pharmaceuticals Incorporated (VRTX) Outperformed in the Third Quarter
November 15, 2022 | finance.yahoo.com
AstraZeneca's (AZN) 3 Cancer Drugs Get CHMP Nod for Expanded Use
November 14, 2022 | finance.yahoo.com
Vertex Pharmaceuticals: Is the Recovery Story Intact?
November 13, 2022 | finance.yahoo.com
Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Intrinsic Value Is Potentially 63% Above Its Share Price
November 10, 2022 | msn.com
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years
November 9, 2022 | finance.yahoo.com
Vertex to Participate in Upcoming Investor Conferences
November 8, 2022 | finance.yahoo.com
Those who invested in Vertex Pharmaceuticals (NASDAQ:VRTX) five years ago are up 105%
November 4, 2022 | finance.yahoo.com
TEVA Misses on Q3 Earnings, Cuts 2022 Sales View, Stock Down
November 4, 2022 | finance.yahoo.com
Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up
See More Headlines
Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VRTX Company Calendar

Last Earnings
11/02/2021
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
1/25/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:VRTX
CUSIP
92532F10
CIK
875320
Web
www.vrtx.com
Phone
(617) 341-6100
Fax
617-576-2109
Employees
3,900
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$305.33
High Stock Price Forecast
$365.00
Low Stock Price Forecast
$222.00
Forecasted Upside/Downside
-3.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.65
Research Coverage
17 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$12.68
Trailing P/E Ratio
24.87
Forward P/E Ratio
24.25
P/E Growth
1.76
Net Income
$2.34 billion
Net Margins
37.62%
Pretax Margin
46.28%
Return on Equity
29.65%
Return on Assets
22.73%

Debt

Debt-to-Equity Ratio
0.03
Current Ratio
4.70
Quick Ratio
4.55

Sales & Book Value

Annual Sales
$7.57 billion
Price / Sales
10.69
Cash Flow
$12.73 per share
Price / Cash Flow
24.77
Book Value
$39.72 per share
Price / Book
7.94

Miscellaneous

Outstanding Shares
256,691,000
Free Float
255,664,000
Market Cap
$80.93 billion
Optionable
Optionable
Beta
0.44

Social Links


Key Executives

  • Dr. Jeffrey Marc Leiden M.D. (Age 66)
    Ph.D., Exec. Chairman
    Comp: $281.98k
  • Dr. Reshma Kewalramani FASNDr. Reshma Kewalramani FASN (Age 49)
    M.D., CEO, Pres & Director
    Comp: $4.27M
  • Mr. Charles F. Wagner Jr.Mr. Charles F. Wagner Jr. (Age 54)
    Exec. VP & CFO
    Comp: $1.85M
  • Mr. Stuart A. Arbuckle B.Sc.Mr. Stuart A. Arbuckle B.Sc. (Age 56)
    Exec. VP & COO
    Comp: $2.56M
  • Dr. Ourania Tatsis Ph.D. (Age 51)
    Exec. VP and Chief Regulatory & Quality Officer
    Comp: $1.33M
  • Ms. Kristen C. AmbroseMs. Kristen C. Ambrose (Age 45)
    Chief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services
  • Dr. David M. Altshuler M.D. (Age 57)
    Ph.D., Exec. VP of Global Research & Chief Scientific Officer
  • Mr. Mike Tirozzi
    SVP and Chief Information & Data Officer
  • Susie Lisa
    Sr. VP of Investor Relations
  • Mr. Damian W. Wilmot Esq. (Age 46)
    Sr. VP, Chief Risk and Compliance Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













VRTX Stock - Frequently Asked Questions

Should I buy or sell Vertex Pharmaceuticals stock right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last twelve months. There are currently 6 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VRTX shares.
View VRTX analyst ratings or view top-rated stocks.

What is Vertex Pharmaceuticals' stock price forecast for 2023?

17 equities research analysts have issued 12 month price targets for Vertex Pharmaceuticals' shares. Their VRTX share price forecasts range from $222.00 to $365.00. On average, they anticipate the company's stock price to reach $305.33 in the next year. This suggests that the stock has a possible downside of 3.2%.
View analysts price targets for VRTX or view top-rated stocks among Wall Street analysts.

How have VRTX shares performed in 2022?

Vertex Pharmaceuticals' stock was trading at $219.60 at the beginning of the year. Since then, VRTX shares have increased by 43.6% and is now trading at $315.30.
View the best growth stocks for 2022 here.

When is Vertex Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, January 25th 2023.
View our VRTX earnings forecast.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced its quarterly earnings data on Tuesday, November, 2nd. The pharmaceutical company reported $3.56 EPS for the quarter, topping the consensus estimate of $2.74 by $0.82. The pharmaceutical company had revenue of $1.98 billion for the quarter, compared to the consensus estimate of $1.85 billion. Vertex Pharmaceuticals had a net margin of 37.62% and a trailing twelve-month return on equity of 29.65%. During the same period in the prior year, the company earned $2.36 EPS.
Read the conference call transcript.

What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?

Vertex Pharmaceuticals issued an update on its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $8.80 billion-$8.90 billion, compared to the consensus revenue estimate of $8.77 billion.

What is Reshma Kewalramani's approval rating as Vertex Pharmaceuticals' CEO?

31 employees have rated Vertex Pharmaceuticals Chief Executive Officer Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among the company's employees.

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), Salesforce (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (9.83%), Vanguard Group Inc. (8.23%), State Street Corp (4.79%), Alliancebernstein L.P. (3.56%), Price T Rowe Associates Inc. MD (2.01%) and Jennison Associates LLC (1.85%). Insiders that own company stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Joy Liu, Kristen Ambrose, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young and Yuchun Lee.
View institutional ownership trends.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $315.30.

How much money does Vertex Pharmaceuticals make?

Vertex Pharmaceuticals (NASDAQ:VRTX) has a market capitalization of $80.93 billion and generates $7.57 billion in revenue each year. The pharmaceutical company earns $2.34 billion in net income (profit) each year or $12.68 on an earnings per share basis.

How many employees does Vertex Pharmaceuticals have?

The company employs 3,900 workers across the globe.

Does Vertex Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Vertex Pharmaceuticals: Aurora Biosciences Corporation, Exonics Therapeutics, Semma Therapeutics, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vectrus, Vertex Farmaceutica do Brasil LTDA, Vertex Holdings Inc., Vertex Pharmaceuticals (Australia) Pty. Ltd., Vertex Pharmaceuticals (CH) GmbH, Vertex Pharmaceuticals (Canada) Incorporated, Vertex Pharmaceuticals (Cayman 509) Limited, Vertex Pharmaceuticals (Cayman 765) Limited, Vertex Pharmaceuticals (Cayman 787) Limited, Vertex Pharmaceuticals (Cayman III) Limited, Vertex Pharmaceuticals (Cayman) Limited, Vertex Pharmaceuticals (Czech Republic) s.r.o, Vertex Pharmaceuticals (Delaware) LLC, Vertex Pharmaceuticals (Distribution) Incorporated, Vertex Pharmaceuticals (Europe) Limited, Vertex Pharmaceuticals (France) SAS, Vertex Pharmaceuticals (Germany) GmbH, Vertex Pharmaceuticals (Ireland) Limited, Vertex Pharmaceuticals (Italy) S.r.L., Vertex Pharmaceuticals (Netherlands) B.V., Vertex Pharmaceuticals (Poland) sp. z.o.o, Vertex Pharmaceuticals (Portugal), Vertex Pharmaceuticals (Puerto Rico) LLC, Vertex Pharmaceuticals (San Diego) LLC, Vertex Pharmaceuticals (Singapore) Pte. Ltd., Vertex Pharmaceuticals (Spain) S.L., Vertex Pharmaceuticals (Sweden) AB, Vertex Pharmaceuticals (U.K.) Limited, Vertex Pharmaceuticals GmbH, Vertex Pharmaceuticals Single Member Societe Anonyme, and Vertex Securities Corporation.
Read More
How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The official website for the company is www.vrtx.com. The pharmaceutical company can be reached via phone at (617) 341-6100, via email at investorinfo@vrtx.com, or via fax at 617-576-2109.

This page (NASDAQ:VRTX) was last updated on 11/28/2022 by MarketBeat.com Staff